2022 World Conference on Lung Cancer (ePosters)-EP08.02-059. EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis

EP08.02-059. EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis

Back to course

Pdf Summary

A network meta-analysis was conducted to compare the efficacy of different first-line treatment strategies in advanced non-small cell lung cancer (NSCLC) with EGFR mutations. The study included 17 randomized controlled trials (RCTs) involving 5,176 patients. The analysis compared seven treatment strategies, including various generations of EGFR tyrosine kinase inhibitors (TKIs) and combination therapies.<br /><br />The results showed that third-generation TKIs had a numerical improvement in both progression-free survival (PFS) and overall survival (OS) compared to second-generation TKIs, TKI plus ramucirumab (RAM), and TKI plus bevacizumab (BVZ). The combination of FG TKI plus chemotherapy (CT) also demonstrated better PFS and significant OS benefit compared to second-generation TKIs and TKI plus BVZ.<br /><br />When comparing FG TKI plus CT to third-generation TKIs, there was a non-significant superior trend in OS. FG TKI plus CT was also associated with higher odds of overall response rate (ORR). Therefore, both third-generation TKIs and FG TKI plus CT were considered more favorable treatment options for first-line therapy in advanced EGFR-mutated NSCLC.<br /><br />However, it is important to note that factors related to patient selection, post-progression therapies, inclusion criteria in the network meta-analysis, and the grouping of different treatments may have contributed to the discrepancies in the results.<br /><br />In conclusion, this network meta-analysis suggests that third-generation TKIs and FG TKI plus CT may be preferred treatment options for first-line therapy in advanced EGFR-mutated NSCLC. Further research is needed to validate these findings and address the limitations of the included studies.

Asset Subtitle

Gilberto de Castro

Meta Tag

Speaker Gilberto de Castro

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

network meta-analysis

first-line treatment strategies

advanced non-small cell lung cancer

NSCLC

EGFR mutations

randomized controlled trials

progression-free survival

overall survival

EGFR tyrosine kinase inhibitors

combination therapies